Literature DB >> 2557965

Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3H]rolipram.

P Kaulen1, G Brüning, H H Schneider, M Sarter, H G Baumgarten.   

Abstract

Rolipram is a clinically effective antidepressant with selective cAMP phosphodiesterase (PDE) inhibiting properties. (+/-)-[3H]Rolipram binds with high affinity (Kd = 2.52 +/- 0.47 nM) to sections of rat brain (Hill number = 0.90 +/- 0.05). Binding is stereospecific. Association of (+/-) [3H]rolipram to sections is rapid (47% of specific binding in the first minute, kobs = 0.52 min-1). Dissociation of (+/-)-[3H]rolipram exhibits non first order kinetics (3 component model; t1/2 = 2.5 min, 50 min and 6 h, respectively). A number of PDE inhibitors reduce (+/-)-[3H]rolipram binding to the level of nonspecific binding ((-)-rolipram, IC50 = 0.9 nM; (+/-)-rolipram, IC50 = 1.5 nM; Ro 20-1724, IC50 = 11 nM; ICI 63.197, IC50 = 35 nM; medazepam, IC50 = 240 nM; diazepam, IC50 = 1200 nM; IBMX, IC50 = 3800 nM). In vitro autoradiography reveals high binding site densities in the cerebellum, olfactory bulb, lateral septal nucleus, frontal cortex, subiculum and CA1 of hippocampus. Most of the labeled structures are part of the limbic system. In vivo autoradiography of (+/-)-[3H]rolipram binding shows much more nonspecific binding than in vitro, nevertheless the distribution pattern of (+/-)-[3H]rolipram binding sites is similar. A comparison of the distribution pattern of (+/-)-[3H]rolipram binding sites with that of an antidepressant (monoamine oxidase inhibitor, monoamine uptake inhibitor) reveals no overlap. Limited, though significant correlations exist with the distribution of beta 1-adrenergic, adenosine1 and glutamate/quisqualate receptors as well as protein kinase C, but not with beta 2-adrenergic receptors and forskolin binding sites.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2557965     DOI: 10.1016/0006-8993(89)91669-7

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

1.  Effects of chronic treatment with a cyclic AMP-selective phosphodiesterase inhibitor, rolipram, on excitatory amino acid neurotransmission systems in young and aged rat brains.

Authors:  H Kato; T Araki; T Chen; X H Liu; T Hiranuma; K Murase; Y Itoyama; K Kogure
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

2.  Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase.

Authors:  R Schmiechen; H H Schneider; H Wachtel
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Effect of nitric oxide synthase inhibitor on age-related changes in second messenger systems and calcium channels in rats.

Authors:  T Araki; H Kato; K Shuto; T Fujiwara; Y Itoyama
Journal:  Metab Brain Dis       Date:  1997-03       Impact factor: 3.584

4.  The low KM-phosphodiesterase inhibitor denbufylline enhances neuronal excitability in guinea pig hippocampus in vitro.

Authors:  B Sutor; C Alzheimer; A Ameri; G ten Bruggencate
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-09       Impact factor: 3.000

5.  Age-dependent changes in second messenger and rolipram receptor systems in the gerbil brain.

Authors:  T Araki; H Kato; Y Kanai; K Kogure
Journal:  J Neural Transm Gen Sect       Date:  1994

6.  Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats.

Authors:  Han-Ting Zhang; Yu Zhao; Ying Huang; Chengjun Deng; Allen T Hopper; Michael De Vivo; Gregory M Rose; James M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  2006-04-04       Impact factor: 4.530

7.  Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase.

Authors:  J E Souness; L C Scott
Journal:  Biochem J       Date:  1993-04-15       Impact factor: 3.857

8.  Cytotoxicity of Zardaverine in Embryonal Rhabdomyosarcoma from a Costello Syndrome Patient.

Authors:  Donna M Cartledge; Katherine M Robbins; Katherine M Drake; Rachel Sternberg; Deborah L Stabley; Karen W Gripp; E Anders Kolb; Katia Sol-Church; Andrew D Napper
Journal:  Front Oncol       Date:  2017-04-03       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.